Joye L. Bramble, PH.D. Appointed Vice President, Pilot Plant Operations for Morphotek, Inc.

Contacts: Philip Sass Morphotek, Inc. 610-423-6106

Suzanne Grogan Eisai Inc. 201-746-2083

Joye l. Bramble, ph.d. APPOINTED vice president, pilot plant operations FOR MORPHOTEK^®, INC.

Exton , PA , May 18, 2010 – Morphotek^®, Inc. today announced the appointment of Joye L. Bramble, Ph.D. as Vice President, Pilot Plant Operations. In this role, Dr. Bramble will have full responsibility for the management and operation of Morphotek’s new pilot manufacturing plant, which will produce biologics to support the company’s early-stage clinical trials. The company broke ground for the new $80 million facility in March 2010 and expects operations to begin by fall 2012. Morphotek^® is a subsidiary of Eisai Inc., the U.S. pharmaceutical operation of Tokyo-based Eisai Co., Ltd.

With more than two decades of experience in the biotechnology industry, Dr. Bramble will play an instrumental role in the introduction of Morphotek’s new pilot manufacturing plant. Dr. Bramble will report to Philip Sass, Ph.D., Executive Vice President and COO of Morphotek, and serve on the company’s Executive Committee.

“We are extremely pleased to welcome Dr. Bramble to the Morphotek management team,” said Dr. Sass. “She possesses a breadth of experience in all aspects of research and development and has an impressive track record of leading the day-to-day operations of pilot plant facilities, both of which will serve her well in helping Morphotek to maximize the efficiencies of its product development process and move closer to its goal of becoming a fully integrated biopharmaceutical company.”

Dr. Bramble most recently served as Executive Director of Business and Research Integration in Research Planning and Integration at Merck Research Labs (MRL) where she led a staff of 150 people at six sites in three countries that provided business operations support to the President of MRL and his management team. This included the development of therapeutic area and capability strategies, long-range operational and capital plans, and portfolio and pipeline management methodologies.

Over the course of her tenure with Merck, which began in 1990, Dr. Bramble assumed positions of increasing responsibility in Vaccine Technology and Engineering, Project Planning and Management, Bioprocess Research and Development, and Bioprocess Clinical Manufacturing and Technology, before assuming her most recent position in Research Planning and Integration. She also was part of the Merck/Schering Plough Research Integration Team that was charged with developing organizational structures, value capture targets and execution time lines to support the merger as well as the governance structures for the new company’s product development activities moving forward.

Dr. Bramble holds a Ph.D. in chemical and biochemical engineering from the University of Pennsylvania and a Bachelor of Chemical Engineering degree from the University of Delaware. She also completed a university fellowship for study abroad at the Institut für Biotechnologie, Eidgenössische Technische Hochschule in Zurich, Switzerland.

About Morphotek

Morphotek^®, Inc., a subsidiary of Eisai Inc., is a biopharmaceutical company specializing in the development of protein and antibody products through the use of novel and proprietary technologies. The technologies have been successfully applied to a variety of molecules that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease. For more information, please visit www.morphotek.com.

Eisai Inc.

Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business with fiscal year 2009 (year ended March 31, 2010) sales of approximately $3.9 billion. Eisai Inc.’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com.